HLA
BPMC

Hamilton Lane Advisors’s Blueprint Medicines BPMC Stock Holding History

Hamilton Lane Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-21,034
Closed -$399K – 63
2016
Q2 		$399K Buy
+21,034
New +$382K 0.19% 50

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Hamilton Lane Advisors's BPMC Position: Q3 2016 in Review

Hamilton Lane Advisors sold out of Blueprint Medicines (BPMC) in Q3 2016, closing a stake of 21,034 shares — an estimated $399K sold.

Hamilton Lane Advisors first reported a position in BPMC in Q2 2016 and held it in 1 quarter. The position peaked at $399K in Q2 2016. 87 funds tracked by Wall St. Rank hold BPMC as of Q3 2016.

  • Hamilton Lane Advisors reported no remaining Blueprint Medicines position as of Q3 2016 after selling out during the quarter.
  • Hamilton Lane Advisors sold 21,034 Blueprint Medicines shares in Q3 2016, an estimated $399K.
  • Hamilton Lane Advisors first reported a position in Blueprint Medicines in Q2 2016 and held it in 1 quarter.
  • Hamilton Lane Advisors's Blueprint Medicines position peaked at $399K in Q2 2016.
  • 87 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2016.

Based on Hamilton Lane Advisors's 13F filing for Q3 2016, filed 19 Oct 2016.